Losarhyd LD JG Dosage

How long did you take this medication to work?
sponsored

Dosage of Losarhyd LD JG in details

sponsored

Losarhyd LD JG Dosage

Generic name: Losartan (Losarhyd LD JG) potassium 50mg, Hydrochlorothiazide (Losarhyd LD JG) 12.5mg

Dosage form: tablet, film coated

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Hypertension

The usual starting dose of Losarhyd LD JG is 50/12.5 (Losartan (Losarhyd LD JG) 50 mg/Hydrochlorothiazide (Losarhyd LD JG) 12.5 mg) once daily. The dosage can be increased after 3 weeks of therapy to a maximum of 100/25 (Losartan (Losarhyd LD JG) 100 mg/Hydrochlorothiazide (Losarhyd LD JG) 25 mg) once daily as needed to control blood pressure.

Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losarhyd LD JG) 50 mg monotherapy with Losarhyd LD JG 50/12.5 once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, the dosage may be increased to two tablets of Losarhyd LD JG 50/12.5 once daily or one tablet of Losarhyd LD JG 100/25 once daily.

Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losarhyd LD JG) 100 mg monotherapy with Losarhyd LD JG 100/12.5 (Losartan (Losarhyd LD JG) 100 mg/Hydrochlorothiazide (Losarhyd LD JG) 12.5 mg) once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losarhyd LD JG 50/12.5 once daily or one tablet of Losarhyd LD JG 100/25 once daily.

Initiate a patient whose blood pressure is inadequately controlled with Hydrochlorothiazide (Losarhyd LD JG) 25 mg once daily, or is controlled but who experiences hypokalemia with this regimen, on Losarhyd LD JG 50/12.5 once daily, reducing the dose of Hydrochlorothiazide (Losarhyd LD JG) without reducing the overall expected antihypertensive response. Evaluate the clinical response to Losarhyd LD JG 50/12.5 and, if blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losarhyd LD JG 50/12.5 once daily or one tablet of Losarhyd LD JG 100/25 once daily.

Hypertensive Patients with Left Ventricular Hypertrophy

In patients whose blood pressure is not adequately controlled on 50 mg Losartan (Losarhyd LD JG) potassium, initiate treatment with Losarhyd LD JG 50/12.5. If additional blood pressure reduction is needed, increase the dose to Losarhyd LD JG 100/12.5, followed by Losarhyd LD JG 100/25. For further blood pressure reduction add other antihypertensives.

More about Losarhyd LD JG (Hydrochlorothiazide (Losarhyd LD JG) / Losartan (Losarhyd LD JG))

Consumer resources

Professional resources

Related treatment guides

What other drugs will affect Losarhyd LD JG?

Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Losarhyd LD JG, especially:

This list is not complete. Other drugs may interact with Losarhyd LD JG, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Losarhyd LD JG interactions

sponsored

Agents Increasing Serum Potassium

Coadministration of Losartan (Losarhyd LD JG) with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.

Lithium

Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of angiotensin II receptor antagonists or thiazide diuretics. Monitor lithium levels in patients receiving Losarhyd LD JG and lithium.

Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors

Losartan (Losarhyd LD JG) Potassium

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including Losartan (Losarhyd LD JG)) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Losartan (Losarhyd LD JG) and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including Losartan (Losarhyd LD JG), may be attenuated by NSAIDs, including selective COX-2 inhibitors.

Hydrochlorothiazide (Losarhyd LD JG)

The administration of a non-steroidal anti-inflammatory agent including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Losarhyd LD JG and non-steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.

In patients receiving diuretic therapy, coadministration of NSAIDs with angiotensin receptor blockers, including Losartan (Losarhyd LD JG), may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Hydrochlorothiazide (Losarhyd LD JG), Losartan (Losarhyd LD JG), and NSAID therapy.

Dual Blockade Of The Renin-Angiotensin System (RAS)

Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

The Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 mL/min), randomized them to lisinopril or placebo on a background of Losartan (Losarhyd LD JG) therapy and followed them for a median of 2.2 years. Patients receiving the combination of Losartan (Losarhyd LD JG) and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end-stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.

Closely monitor blood pressure, renal function, and electrolytes in patients on Losarhyd LD JG and other agents that affect the RAS.

Do not coadminister aliskiren with Losarhyd LD JG in patients with diabetes. Avoid use of aliskiren with Losarhyd LD JG in patients with renal impairment (GFR < 60 mL/min).

The Use Of Hydrochlorothiazide (Losarhyd LD JG) With Other Drugs

When administered concurrently, the following drugs may interact with thiazide diuretics :

Antidiabetic drugs (oral agents and insulin) — dosage adjustment of the antidiabetic drug may be required.

Cholestyramine and colestipol resins — Absorption of Hydrochlorothiazide (Losarhyd LD JG) is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the Hydrochlorothiazide (Losarhyd LD JG) and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Stagger the dosage of Hydrochlorothiazide (Losarhyd LD JG) and the resin such that Hydrochlorothiazide (Losarhyd LD JG) is administered at least 4 hours before or 4 to 6 hours after the administration of the resin.


sponsored

References

  1. DailyMed. "AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DailyMed. "LOSARTAN POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  3. FDA/SPL Indexing Data. "JMS50MPO89: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Losarhyd LD JG are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Losarhyd LD JG. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 1 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved